RE: RE: more of the sameIn March of this year they started Phase II trials in Japan
https://www.pr-inside.com/desmoteplase-enters-clinical-phase-ii-in-japan-in--r1777534.htm
Desmoteplase is a novel, highly fibrin-specific thrombolytic agent in phase III of clinical development. In 2009, 2 large trials (DIAS-3 and DIAS-4) were started (www.clinicaltrials.gov: NCT00790920 & NCT00856661), and the results of these studies will determine whether desmoteplase will gain marketing authorization as a safe and effective treatment for patients with acute ischaemic stroke. Filing with health authorities is estimated in 2012. The Danish pharmaceutical company, H. Lundbeck A/S, owns the worldwide rights to desmoteplase